Water Vapor Ablation for Prostate Cancer: Long-Term Registry
ConditionProstate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
AgeNot listed
SponsorFrancis Medical Inc.
About this trial
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Eligibility criteria
Qualifiers
Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.
Participant is willing and able to provide written informed consent.
Disqualifiers
Contraindications per the Vanquish IFU
Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.
Trial design
Treatments tested in this trial
- Vanquish Therapy
Treatment groups
2,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov